Nurix Therapeutics, Inc.
NRIX · NASDAQ
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | $7,894 | $44,056 | $18,453 | $13,284 |
| % Growth | -82.1% | 138.7% | 38.9% | – |
| Cost of Goods Sold | $5,000 | $78,096 | $69,663 | $67,224 |
| Gross Profit | $2,894 | -$34,040 | -$51,210 | -$53,940 |
| % Margin | 36.7% | -77.3% | -277.5% | -406.1% |
| R&D Expenses | $86,120 | $78,096 | $69,663 | $67,224 |
| G&A Expenses | $13,159 | $14,282 | $11,654 | $10,717 |
| SG&A Expenses | $13,159 | $14,282 | $11,654 | $10,717 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$5,000 | -$78,096 | -$69,663 | -$67,224 |
| Operating Expenses | $94,279 | $14,282 | $11,654 | $10,717 |
| Operating Income | -$91,385 | -$48,322 | -$62,864 | -$64,657 |
| % Margin | -1,157.7% | -109.7% | -340.7% | -486.7% |
| Other Income/Exp. Net | $4,964 | $5,618 | $6,513 | $6,116 |
| Pre-Tax Income | -$86,421 | -$42,704 | -$56,351 | -$58,541 |
| Tax Expense | $0 | $760 | $0 | $8 |
| Net Income | -$86,421 | -$43,464 | -$56,351 | -$58,549 |
| % Margin | -1,094.8% | -98.7% | -305.4% | -440.7% |
| EPS | -1.03 | -0.52 | -0.67 | -0.75 |
| % Growth | -98.1% | 22.4% | 10.7% | – |
| EPS Diluted | -1.03 | -0.52 | -0.67 | -0.75 |
| Weighted Avg Shares Out | 84,159 | 83,882 | 83,561 | 78,411 |
| Weighted Avg Shares Out Dil | 84,159 | 83,882 | 83,561 | 78,411 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,964 | $5,618 | $6,513 | $6,116 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5,000 | $2,242 | $2,350 | $1,249 |
| EBITDA | -$81,421 | -$46,080 | -$60,514 | -$63,408 |
| % Margin | -1,031.4% | -104.6% | -327.9% | -477.3% |